Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 12/20 | 0.54 |
| ▸ | PGR | P06401 | 2/20 | 0.49 |
| ▸ | GABRP | O00591 | 1/20 | 0.48 |
| ▸ | GABRD | O14764 | 1/20 | 0.48 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.48 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.48 |
| ▸ | KLK3 | P07288 | 1/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.48 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.48 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.48 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.48 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.48 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.48 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.48 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.48 |
| ▸ | GABRE | P78334 | 1/20 | 0.48 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2119762 | 0.88 | AR (0.56) | ARPGRGABRPGABRDNR1I2 | |
| SCHEMBL633856 | 0.84 | AR (0.56) | ARPGR | |
| SCHEMBL633930 | 0.84 | AR (0.59) | ARPGR | |
| SCHEMBL2122275 | 0.81 | AR (0.67) | ARPGR | |
| SCHEMBL4023707 | 0.74 | AR (0.73) | ARPGR | |
| SCHEMBL23080486 | 0.73 | AR (0.66) | ARPGRGABRPGABRDNR1I2 | |
| SCHEMBL7035063 | 0.73 | AR (0.87) | ARPGRGABRPGABRDNR1I2 | |
| SCHEMBL1716022 | 0.73 | AR (0.69) | ARPGR | |
| SCHEMBL16845498 | 0.73 | AR (0.66) | ARPGR | |
| SCHEMBL21996132 | 0.73 | AR (0.66) | ARPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2419422-B1 | IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AND USE THEREOF AS A MEDICAMENT | IPSEN PHARMA SAS (FR) | 2014-10-15 | — | — | EP | disclosed |
| US-8624037-B2 | Imidazolidine-2,4-dione derivatives and use thereof as a medicament | IPSEN PHARMA S.A.S. (FR) | 2014-01-07 | — | — | US | disclosed |
| US-20120095068-A1 | IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AND USE THEREOF AS A MEDICAMENT | IPSEN PHARMA S.A.S. (FR) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095068-A1 | IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AND USE THEREOF AS A MEDICAMENT | MKI67, CCNI, CCNA1 | AR 2479/4885PGR 658/4885GABRP 3010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.